Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Common antibiotic could boost stroke recovery in major new trial

NCT ID NCT07237048

Disease control Sponsor: Joyce Chen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the antibiotic minocycline to standard stroke care can improve survival and reduce disability in adults who have had a moderate stroke. About 1,164 participants will be randomly assigned to receive either minocycline pills for five days plus usual care, or usual care alone. Researchers will track neurological recovery and complications over 90 days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 1,164 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

\* Inclusion criteria In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Age \>/=18 2. NIHSS 5-20 \*National Institutes of Health Stroke Scale\* 3. Acute onset neurological deficit consistent with acute ischemic stroke or on imaging consistent with acute ischemia as defined by WHO \*(World Health Organization) \* guidelines or acute onset of neurological deficits with intracerebral Hemorrhage on imaging consistent with intracerebral bleed 4. The onset of neurological symptoms less than 24 hours * Exclusion criteria An individual who meets any of the following criteria is excluded from participation in this study: 1. Clinically stroke is not suspected 2. Allergic to the Tetracycline group of medications or Intolerance to Minocycline 3. Pregnancy or suspected pregnancy or breastfeeding 4. Previous history of intolerance to Minocycline 5. Acute or chronic renal failure (stage III with GFR \*(Glomerular Filtration Rate) \* or Creatinine threshold) 6. Any patients with contraindications to undergo CT (Computed Tomography) / MRI (Magnetic Resonance Imaging) 7. Life expectancy less than one year or severe co-morbidities or comfort measure only (CMO) on admission 8. Pre-existing infectious disease requiring antibiotics 9. Inability to tolerate enteral medications/feeds 10. Patient/ family refusal

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebrovascular accident (stroke) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cyclopia sequence hemorrhagic stroke intracerebral hemorrhage ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebrovascular accident (stroke) Hemorrhagic strokes Intracerebral haemorrhage, ich Ischemia stroke Morbidity Mortality Stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Maimonides Medical Center

    RECRUITING

    Brooklyn, New York, 11219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.